Results Of Preliminary Trials Suggests Russia’s COVID-19 Vaccine Is Safe And Induces Immune Response
Results of preliminary trials suggest that the coronavirus vaccine that Russia made is safe to use and induces an immune response.
Back in August this year, Russia announced that the vaccine for the coronavirus, which is called the Sputnik V, would go into mass production.
However, experts all over the world were not sure if the vaccine would be safe because of the fast production time.
It is reported that the vaccine, which is developed by the Gamaleya Research Institute of Moscow, causes no major adverse effects.
It was reported that the vaccine managed to induce antibodies in all participants in 2 early rounds of testing.
The results of the trials were published in The Lancet, a medical journal, on September 4, 2020.
However, experts that reviewed the study said that results did not fully prove that the vaccine was safe or effective to use.
Vladimir Putin, the President of Russia, gave regulatory approval to Sputnik V on August 11, 2020, claiming that shortened trials had shown that it was safe to use.
The President of Russia also claimed that people that get vaccinated will form long-term immunity.
Putin earlier described that the vaccine is important for the world.
Earlier this year, Vladimir Putin talked about the virus, where he said:
I know that it works quite effectively, forms strong immunity, and I repeat, it has passed all the needed checks.
The results that were published in the study were about 7q6 volunteers that took part in phase 1 and phase 2 of the testing.
The people that took part in the study are all healthy adults that are aged between the ages of 18 and 60. The volunteers remained in the hospital for 28 days after vaccination.
2 variants of the vaccine were trailed, which are the frozen formulation and a freeze-dried alternative.
The study claims that Sputnik V induced antibody response just within 21 days without showing no adverse effects. The study went on for 42 days.
The study also said that the Sputnik V vaccine triggered a T cell response, which is beneficial in the long-term against the virus.
Phase 3 of the testing has already started in Russia.
It is reported that 40,000 volunteers will be getting injected with the Sputnik V vaccine.